Meribank Biotech Co., Ltd (TPEX:4724)
7.00
-0.97 (-12.17%)
Nov 20, 2026, 1:37 PM CST
Meribank Biotech Revenue
Meribank Biotech had revenue of 187.13M TWD in the half year ending June 30, 2026, with 43.59% growth. This brings the company's total for the last twelve months to 408.48M, down -16.04% year-over-year. In the year 2025, Meribank Biotech had annual revenue of 471.76M with 28.75% growth. That makes Meribank Biotech the 36,439th largest company in the world by revenue and 1,901st in Taiwan.
Revenue (ttm)
408.48M
Revenue Growth
-16.04%
P/S Ratio
1.64
Revenue / Employee
2.88M
Employees
142
Market Cap
671.83M
Revenue by Segment
- Stem Cell Department 246.16M 52.2%
- Management Consulting Department 159.76M 33.9%
- Other 65.85M 14.0%
Fiscal year ended Dec 31, 2025 See the full Meribank Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 471.76M | 105.33M | 28.75% |
| Dec 31, 2024 | 366.43M | 132.09M | 56.37% |
| Dec 31, 2023 | 234.34M | 54.22M | 30.10% |
| Dec 31, 2022 | 180.12M | 17.04M | 10.45% |
| Dec 31, 2021 | 163.08M | -31.32M | -16.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 695.30M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 266.56M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 241.13M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Holy Stone Healthcare | 47.51M |